Pulse Biosciences (NASDAQ:PLSE) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Pulse Biosciences received a "sell (D-)" rating from Weiss Ratings, while Oppenheimer has issued an "outperform" rating with a price target of $22.00.
• The company's stock currently has a consensus rating of "Hold" with a target price of $22.00, despite a recent earnings report showing a miss on estimates.
• Insider selling activity was noted, with key executives reducing their holdings significantly, indicating potential concerns about the company’s performance.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Separately, Oppenheimer assumed coverage on shares of Pulse Biosciences in a research report on Monday, July 7th. They issued an "outperform" rating and a $22.00 price objective for the company. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $22.00.

Pulse Biosciences Stock Up 0.4%

Shares of NASDAQ:PLSE opened at $19.94 on Wednesday. The firm has a market capitalization of $1.34 billion, a PE ratio of -18.99 and a beta of 1.79. Pulse Biosciences has a twelve month low of $13.77 and a twelve month high of $25.00. The company has a 50-day moving average price of $16.40 and a two-hundred day moving average price of $16.29.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02).

Insider Activity

In other news, insider Kevin Patrick Danahy sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $18.49, for a total value of $369,800.00. Following the completion of the transaction, the insider directly owned 43,298 shares in the company, valued at approximately $800,580.02. This trade represents a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Darrin Uecker sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $15.77, for a total transaction of $394,250.00. Following the completion of the transaction, the chief technology officer owned 122,872 shares of the company's stock, valued at $1,937,691.44. This trade represents a 16.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 95,000 shares of company stock worth $1,550,380. 74.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently bought and sold shares of the stock. Nuveen LLC bought a new stake in shares of Pulse Biosciences in the 1st quarter worth approximately $915,000. Pandora Wealth Inc. bought a new stake in shares of Pulse Biosciences in the 1st quarter worth approximately $828,000. Geode Capital Management LLC lifted its holdings in shares of Pulse Biosciences by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 499,464 shares of the company's stock worth $7,538,000 after acquiring an additional 33,744 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $466,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $388,000. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.